1. Thomas, E, Storb, R, Clift, RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832–843.
Google Scholar | Crossref | Medline | ISI2. Champlin, R, Khouri, I, Komblau, S, et al. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology 1999; 13: 621–628; discussion 631, 635–628, 641.
Google Scholar | Medline3. Champlin, R . T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 687–698.
Google Scholar | Crossref | Medline | ISI4. Storek, J, Mohty, M, Boelens, JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 959–970.
Google Scholar | Crossref | Medline5. Bacigalupo, A, Lamparelli, T, Barisione, G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.
Google Scholar | Crossref | Medline | ISI6. Bacigalupo, A, Oneto, R, Lamparelli, T, et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093–1096.
Google Scholar | Crossref | Medline | ISI7. Finke, J, Bethge, WA, Schmoor, C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.
Google Scholar | Crossref | Medline | ISI8. Mohty, M, Labopin, M, Balere, ML, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010; 24: 1867–1874.
Google Scholar | Crossref | Medline9. Soiffer, RJ, Lerademacher, J, Ho, V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–6970.
Google Scholar | Crossref | Medline10. Shichijo, T, Fuji, S, Nagler, A, et al. Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose? Bone Marrow Transplant 2020; 55: 505–522.
Google Scholar | Crossref | Medline11. Feng, X, Kajigaya, S, Solomou, EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008; 111: 3675–3683.
Google Scholar | Crossref | Medline | ISI12. Admiraal, R, Nierkens, S, de Witte, MA, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol 2017; 4: e183–e191.
Google Scholar | Crossref | Medline13. Kennedy, VE, Chen, H, Savani, BN, et al. Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count. Biol Blood Marrow Transplant 2018; 24: 150–155.
Google Scholar | Crossref | Medline14. Modi, D, Kim, S, Surapaneni, M, et al. Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation. Leuk Lymphoma 2020; 61: 3137–3145.
Google Scholar | Crossref | Medline15. Woo, GU, Hong, J, Kim, H, et al. Preconditioning absolute lymphocyte count and transplantation outcomes in matched related donor allogeneic hematopoietic stem cell transplantation recipients with reduced-intensity conditioning and antithymocyte globulin treatment. Biol Blood Marrow Transplant 2020; 26: 1855–1860.
Google Scholar | Crossref | Medline16. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007; 18: 800–804.
Google Scholar | Crossref | Medline | ISI17. Gratwohl, A . The EBMT risk score. Bone Marrow Transplant 2012; 47: 749–756.
Google Scholar | Crossref | Medline18. Glucksberg, H, Storb, R, Fefer, A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Google Scholar | Crossref | Medline | ISI19. Jagasia, MH, Greinix, HT, Arora, M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I . The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015; 21: 389–401.e381.
Google Scholar20. Bosch, M, Dhadda, M, Hoegh-Petersen, M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012; 14: 1258–1275.
Google Scholar | Crossref | Medline21. Soiffer, RJ, Kim, HT, McGuirk, J, et al. Prospective, randomized, double-blind, phase III clinical trial of anti-t-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol 2017; 35: 4003–4011.
Google Scholar | Crossref | Medline22. O’Donnell, PH, Dolan, ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009; 15: 4806–4814.
Google Scholar | Crossref | Medline | ISI23. Kim, HJ, Min, WS, Cho, BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704–717.
Google Scholar | Crossref | Medline24. Morishima, Y, Kawase, T, Malkki, M, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1197–1203.
Google Scholar | Crossref | Medline25. Park, SS, Kwak, DH, Jeon, YW, et al. Beneficial role of low-dose antithymocyte globulin in unrelated stem cell transplantation for adult patients with acquired severe aplastic anemia: reduction of graft-versus-host disease and improvement of graft-versus-host disease-free, failure-free survival rate. Biol Blood Marrow Transplant 2017; 23: 1498–1508.
Google Scholar | Medline26. Hashmi, SK . Individualizing optimal dosing of antithymocyte globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2018; 24: 2–3.
Google Scholar | Crossref | Medline